ROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. MGNX, a biopharmaceutical firm targeted on discovering, growing, manufacturing and commercializing revolutionary antibody-based therapeutics for the remedy of most cancers, right this moment introduced a poster presentation referring to Section 2 knowledge of vobramitamab duocarmazine in metastatic castration-resistant prostate most cancers (mCRPC) on the European Society for Medical Oncology (ESMO) Congress, happening in Barcelona, Spain from September 13-17, 2024.
The next poster will probably be out there on Sunday, September 15, 2024:
TAMARACK: Randomized Section 2 trial of the B7-H3 concentrating on antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate most cancers (mCRPC)
Presenter / Lead Creator: Johann de Bono, M.D., M.Sc., Ph.D., FRCP, FMedSci, Division of Scientific Research, Royal Marsden Hospital Institute of Most cancers Analysis, Sutton, UK
Presentation ID: 1654P
Session Date: Sunday, September 15, 2024
Poster Show Time: 9:00 a.m. – 5:00 p.m. CEST
The summary submitted to ESMO in Might 2024, now out there on the ESMO web site, was primarily based on a knowledge cut-off from April 12, 2024, and the poster will report knowledge from a July 9, 2024, knowledge cut-off. Information to be introduced at ESMO will embrace up to date security and efficacy knowledge, together with the research’s major endpoint of landmark 6-month radiographic progression-free survival (rPFS), in addition to immature median rPFS which will change as extra PFS occasions accrue. The poster to be introduced at ESMO will probably be printed beneath “Occasions & Shows” within the Investor Relations part of MacroGenics’ web site at on September 15, 2024.
Convention Name
The Firm anticipates internet hosting a convention name to debate the TAMARACK poster knowledge and supply a common company replace on Monday, September 16, 2024, at 8:00 a.m. ET. The decision will probably be led by Scott Koenig, M.D., Ph.D., President and Chief Govt Officer; Stephen Eck, M.D., Ph.D., Senior Vice President – Scientific Growth and Chief Medical Officer; and Jim Karrels, Senior Vice President – Chief Monetary Officer.
To take part through phone, please register upfront at this link. Upon registration, all phone contributors will obtain a affirmation electronic mail detailing methods to be part of the convention name, together with the dial-in quantity together with a novel passcode and registrant ID that can be utilized to entry the decision. The listen-only webcast of the convention name may be accessed beneath “Occasions & Shows” within the Investor Relations part of the Firm’s web site at . A recorded replay of the webcast will probably be out there shortly after the conclusion of the decision and archived on the Firm’s web site for 30 days following the decision.
About MacroGenics, Inc.
MacroGenics (the Firm) is a biopharmaceutical firm targeted on discovering, growing, manufacturing and commercializing revolutionary monoclonal antibody-based therapeutics for the remedy of most cancers. The Firm generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based know-how platforms, which have applicability throughout broad therapeutic domains. The mix of MacroGenics’ know-how platforms and protein engineering experience has allowed the Firm to generate promising product candidates and enter into a number of strategic collaborations with international pharmaceutical and biotechnology firms. For extra data, please see the Firm’s web site at www.macrogenics.com. MacroGenics, the MacroGenics emblem, MARGENZA and DART are logos or registered logos of MacroGenics, Inc.
Cautionary Notice on Ahead-Wanting Statements
Any statements on this press launch about future expectations, plans and prospects for MacroGenics (“Firm”), together with statements concerning the Firm’s technique, future operations, scientific improvement of and regulatory plans for the Firm’s therapeutic candidates, together with trial design, initiation and enrollment in scientific trials, anticipated timing of outcomes from scientific trials, discussions with regulatory companies, business prospects of or product revenues from the Firm’s merchandise and product candidates, if permitted, manufacturing providers income, milestone or opt-in funds from the Firm’s collaborators, the Firm’s anticipated milestones and future expectations and plans and prospects for the Firm, in addition to future international internet gross sales of TZIELD and the Firm’s potential to attain the milestone funds set forth beneath the phrases of the settlement with DRI (or its successors or assigns with respect to such settlement), the Firm’s present money assets supporting our deliberate working bills and capital necessities into 2026 and different statements containing the phrases “topic to”, “consider”, “anticipate”, “plan”, “anticipate”, “intend”, “estimate”, “potential,” “venture”, “might”, “will”, “ought to”, “would”, “might”, “can”, the negatives thereof, variations thereon and comparable expressions, or by discussions of technique represent forward-looking statements throughout the that means of Part 27A of the Securities Act of 1933 and Part 21E of the Securities Trade Act of 1934. Precise outcomes might differ materially from these indicated by such forward-looking statements on account of numerous necessary elements, together with: dangers that TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or some other product candidate’s income, bills and prices will not be as anticipated, dangers referring to TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or some other product candidate’s market acceptance, competitors, reimbursement and regulatory actions; future knowledge updates, particularly timing and outcomes of mature median radiographic progression-free survival, different efficacy and security knowledge with respect to vobramitamab duocarmazine; our potential to supply manufacturing providers to our prospects; the uncertainties inherent within the initiation and enrollment of future scientific trials; the supply of financing to fund the interior improvement of our product candidates; expectations of increasing ongoing scientific trials; availability and timing of knowledge from ongoing scientific trials; expectations for the timing and steps required within the regulatory overview course of; expectations for regulatory approvals; expectations of future milestone funds; the influence of aggressive merchandise; our potential to enter into agreements with strategic companions and different issues that would have an effect on the supply or business potential of the Firm’s product candidates; enterprise, financial or political disruptions on account of catastrophes or different occasions, together with pure disasters, terrorist assaults, civil unrest and precise or threatened armed battle, or public well being crises; prices of litigation and the failure to efficiently defend lawsuits and different claims towards us; and different dangers described within the Firm’s filings with the Securities and Trade Fee. As well as, the forward-looking statements included on this press launch characterize the Firm’s views solely as of the date hereof. The Firm anticipates that subsequent occasions and developments will trigger the Firm’s views to vary. Nonetheless, whereas the Firm might elect to replace these forward-looking statements sooner or later sooner or later, the Firm particularly disclaims any obligation to take action, besides as could also be required by regulation. These forward-looking statements shouldn’t be relied upon as representing the Firm’s views as of any date subsequent to the date hereof.
###
CONTACTS: Jim Karrels, Senior Vice President, CFO 1-301-251-5172, [email protected]
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
